PVCs and Intramural Origins: A New Hope for Heart Rhythm
"Variant Ventricular Arrhythmias: How Multi-Site Ablation Changes the Game."
Ventricular arrhythmias (VAs), including ventricular tachycardia (VT) and premature ventricular contractions (PVCs), are heart rhythm disturbances that originate in the ventricles. When these arrhythmias occur in individuals without underlying structural heart disease, they are termed idiopathic ventricular arrhythmias. While many originate from the right ventricular outflow tract (RVOT), some arise from the left ventricular outflow tract (LVOT) or papillary muscles, presenting unique challenges for treatment.
Pinpointing the exact origin of LVOT VAs can be difficult because they can arise from various anatomical structures such as the subaortic region, coronary cusps, the aortic-mitral continuity, the coronary venous system, and the left ventricular summit. Traditional ablation methods, which aim to eliminate the arrhythmia's source, may be less effective when the origin is deep within the heart muscle (intramural), often requiring multiple procedures and yielding suboptimal results.
New research offers a promising approach for patients with intramural LVOT VAs. This article will delve into a study that investigates the benefits of sequential ablation of multiple early activation sites. By targeting several locations where the arrhythmia initiates, this technique aims to improve both acute and long-term outcomes for individuals with these challenging heart rhythm conditions.
Measured Burden and Outcomes
Recent studies continue to evaluate PVC burden, patient demographics, time since diagnosis, pharmacotherapy history, and cardiovascular history as important clinical data in catheter-ablation research. A 2024 real-world study included 120 patients undergoing ablation for ventricular tachycardia or PVCs, including 51 patients treated for PVCs; 70% of the cohort was male, and the mean age was 55.3 years. Newer pulsed-field ablation evidence reports high acute success but relatively modest long-term outcomes for PVC ablation, indicating that larger prospective studies and further technical refinement remain necessary.
The Standard Ablation Path
Catheter ablation has emerged as a first-line therapy for selected patients whose PVCs cause disabling symptoms, left-ventricular systolic dysfunction, or PVC-induced ventricular fibrillation, with reported high efficacy and low complication risk. Radiofrequency ablation remains the standard approach for ventricular arrhythmias, but its efficacy can be limited by complex myocardial substrates. Reviews of difficult PVC and ventricular-tachycardia cases therefore examine advanced strategies for patients who do not respond adequately to typical ablation techniques.
From Mapping to Substrate Modification
PVCs are commonly described as ventricular beats initiated by Purkinje fibers rather than by the sinoatrial node, and in otherwise healthy hearts they most commonly arise near the right-ventricular outflow tract. Earlier ablation practice primarily used activation, entrainment, or pace mapping to target single or linear targets in solitary, fixed, reproducible arrhythmia mechanisms. For hemodynamically unstable or pleomorphic ventricular arrhythmias, substrate modification has increasingly been used, although it can require extensive ablation and risk nonspecific myocyte loss in already compromised ventricles.
Why Targeting Multiple Sites Matters in Intramural PVCs
A study was conducted involving 116 patients undergoing ablation for symptomatic LVOT VAs. Of these, 15 patients (13%) were identified as having multiple sites of early activation. These patients often presented with unique characteristics; including shorter pre-QRS activation times compared to those with a single early activation site (-26 ± 3 msec vs -38 ± 6 msec, p < 0.005).
- Sequential Ablation: The research team performed sequential ablation on multiple early activation sites, achieving arrhythmia suppression in 93% of patients.
- Long-Term Success: Over a follow-up period of approximately 21.5 months, patients who underwent successful multi-site ablation remained free from clinical VAs.
- Location Matters: Activation mapping pinpointed the most common sites as coronary cusps (86.7%), AMC (86.7%), and the LV summit (80%).
Emerging Tools for Difficult PVCs
Recent work highlights pulsed-field ablation as a novel strategy for PVCs arising from intracavitary structures such as papillary muscles and the moderator band, which can be challenging to treat. A contemporary review also places PFA alongside medical therapy and catheter ablation as part of the evolving management of PVCs. Comparative evidence suggests that catheter ablation can reduce PVC recurrence, burden, and frequency compared with antiarrhythmic drugs, although patient symptoms, quality of life, and cost-effectiveness remain insufficiently studied.
Remaining Uncertainties
The promise of intramural and pulsed-field approaches does not eliminate the possibility of incomplete treatment, recurrence, procedural complications, or uncertain long-term benefit. Outcomes may vary with arrhythmia location, myocardial substrate, patient characteristics, and the experience of the treating center. Because the evidence base is still developing, treatment decisions require balancing potential symptom and burden reduction against unresolved risks and limitations.
Ablation Versus Medication
Evidence reviews describe substantial variability in the use of antiarrhythmic-drug therapy and catheter ablation for PVCs. Catheter ablation appears capable of reducing PVC recurrence, burden, and frequency compared with antiarrhythmic drugs, but comparative data on symptoms, quality of life, and cost-effectiveness remain limited. Separate research on ventricular tachycardia in ischemic heart disease addresses catheter ablation and antiarrhythmic drugs in a more complex population, so those findings should not be treated as direct evidence for every patient with PVCs.
The Future of PVC Ablation: Personalized and Precise
This research indicates a significant advancement in treating ventricular arrhythmias, particularly those with intramural origins. The approach of mapping and ablating multiple activation sites offers a more effective strategy for achieving both acute and long-term arrhythmia suppression.
A Promising but Incomplete Shift
Intramural-origin PVCs represent a difficult treatment problem because conventional energy delivery may not reach the relevant tissue adequately. Emerging approaches may expand the options for patients whose arrhythmias remain difficult to control, but early-stage evidence does not yet establish a universally superior technique. The most defensible outlook is cautious optimism: better targeting and delivery could improve outcomes, while long-term comparative validation is still needed.
The Next PFA Frontier
Reviews of pulsed-field ablation describe ongoing preclinical and clinical work in ventricular-arrhythmia ablation, alongside broader development in atrial fibrillation. Animal studies and human case reports involving PVCs and ventricular tachycardia are considered promising, but it remains unclear whether commercial adoption of PFA in the ventricles will produce benefits comparable to those seen in the atrium. Future progress will depend on continued studies that clarify effectiveness, safety, and practical delivery strategies.
Access, Evidence, and Technical Limits
Intramyocardial needle ablation is being investigated for refractory ventricular tachycardia and PVCs, but studies defining its effectiveness and safety remain limited. Pulsed-field ablation offers a different model as a nonthermal, cell-selective technique based on irreversible electroporation, with early clinical experience supporting continued investigation in ventricular arrhythmias. These approaches may address difficult substrates, yet limited evidence and the need for specialized expertise remain important systemic challenges.
Treatment in Real-World Practice
Real-world data describe catheter ablation as an increasingly effective and safe therapy for ventricular arrhythmias, including frequent PVCs, when performed in experienced centers. Research has examined whether targeting all PVC morphologies rather than only the dominant morphology changes outcomes. A retrospective multicenter study also compared multipolar mapping with a multielectrode catheter against point-by-point mapping with the ablation catheter, underscoring how mapping strategy can shape practical care.
While the study acknowledges limitations such as small sample size and the specialized expertise required, the findings underscore the importance of personalized treatment strategies based on detailed electrophysiological mapping. As technology advances, more precise and less invasive ablation techniques are likely to emerge, further improving outcomes for patients with VAs.
For individuals experiencing frequent or symptomatic PVCs, consulting with a cardiologist or electrophysiologist is crucial to determine the most appropriate diagnostic and treatment options. This research offers hope for those who have not found relief through traditional ablation methods.